Video

Finding Answers to Your First Questions

Related Videos
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Related Content
Illustration of woman with blonde hair.
March 13th 2025

Trusting My Stage 4 Breast Cancer Body

Martha Carlson
Practicing consistency has made a difference for me while living with stage 4 breast cancer.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of man and doctor.
March 11th 2025

First Patient Enrolled in Phase 3 Recurrent Prostate Cancer Trial

Ryan Scott
The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence following a prostatectomy.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Illustration of liver.
March 10th 2025

Lenvima Plus Keytruda With TACE May Improve Liver Cancer Outcomes

Alex Biese
For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes.
green background with white text indicating FDA Approval, What You Need to Know
March 8th 2025

FDA Approves Biosimilars for Cancer-Related Skeletal Events

Alex Biese
The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.